Accueil>>Signaling Pathways>> Antibody-drug Conjugate/ADC Related>> ADC Linker>>S-(1-Hydroxy-2-methylpropan-2-yl) methanesulfonothioate

S-(1-Hydroxy-2-methylpropan-2-yl) methanesulfonothioate

Catalog No.GC61257

Le méthanesulfonothioate de S-(1-hydroxy-2-méthylpropan-2-yl) est un lieur ADC clivable au glutathion utilisé pour les conjugués anticorps-médicament (ADC) et fait référence À la composition de la chaÎne alkyle. Le méthanesulfonothioate de S-(1-hydroxy-2-méthylpropan-2-yle) est la partie de liaison des molécules employées À des fins de fixation de mAb.

Products are for research use only. Not for human use. We do not sell to patients.

S-(1-Hydroxy-2-methylpropan-2-yl) methanesulfonothioate Chemical Structure

Cas No.: 2127875-65-2

Taille Prix Stock Qté
50mg
445,00 $US
En stock
100mg
630,00 $US
En stock
250mg
908,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

S-(1-Hydroxy-2-methylpropan-2-yl) methanesulfonothioate is a glutathione cleavable ADC linker used for the antibody-drug conjugates (ADCs) and refers to the Alkyl-Chain composition. S-(1-Hydroxy-2-methylpropan-2-yl) methanesulfonothioate is the linker portions of the molecules employed for mAb attachment purposes[1].

[1]. Pillow TH, et al. Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity. ChemMedChem. 2019 Oct 31.

Avis

Review for S-(1-Hydroxy-2-methylpropan-2-yl) methanesulfonothioate

Average Rating: 5 ★★★★★ (Based on Reviews and 18 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for S-(1-Hydroxy-2-methylpropan-2-yl) methanesulfonothioate

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.